About io biotech inc - IOBT
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.
IOBT At a Glance
IO Biotech, Inc.
Ole Maaløes Vej 3
Copenhagen, North Denmark 2200
| Phone | 45-70-70-29-80 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -95,491,000.00 | |
| Sector | Health Technology | Employees | 80 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
IOBT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.289 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.026 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.768 |
IOBT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,193,637.50 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
IOBT Liquidity
| Current Ratio | 3.333 |
| Quick Ratio | 3.333 |
| Cash Ratio | 3.081 |
IOBT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -87.439 |
| Return on Equity | -105.997 |
| Return on Total Capital | -195.158 |
| Return on Invested Capital | -104.24 |
IOBT Capital Structure
| Total Debt to Total Equity | 4.073 |
| Total Debt to Total Capital | 3.914 |
| Total Debt to Total Assets | 2.829 |
| Long-Term Debt to Equity | 2.548 |
| Long-Term Debt to Total Capital | 2.448 |